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Abstract Single chain variable fragments (scFv) of the murine
monoclonal antibody HD37 specific to human B-cell antigen
CD19 were constructed by joining the VH and VL domains with
linkers of 18, 10, 1 and 0 residues. ScFv-18 formed monomers,
dimers and small amounts of tetramers; scFv-10 formed dimers
and small amounts of tetramers; scFv-1 formed exclusively
tetramers; scFv-0 formed exclusively trimers. The affinities of
the scFv-10 (diabody) and scFv-1 (tetrabody) were approxi-
mately 1.5- and 2.5-fold higher, respectively, than that of the
scFv-0 (triabody). The tetrabody displayed a significantly
prolonged association with cell-bound antigen (t1=2 cell surface
retention at 37‡C of 26.6 min) compared to both the diabody
(13.3 min) and triabody (6.7 min). This increase in avidity of the
tetrabody combined with its larger size could prove to be
particularly advantageous for imaging and the immunotherapy of
B-cell malignancies.
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1. Introduction
A major goal of antibody-based tumor targeting has been
to speci¢cally deliver a variety of agents such as radioisotopes,
drugs, toxins, lymphokines, and enzymes for imaging and
therapy. Intact IgG molecules are large (150 kDa) glycopro-
teins that exhibit a slow systemic clearance, often leading to
poor tumor targeting speci¢city. Smaller antibody-derived
molecules include enzymatically produced 50 kDa Fab frag-
ments and engineered 25 kDa single chain Fv (scFv) consist-
ing of the heavy and light chain variable regions (VH and VL)
connected by a £exible 14^24 amino acid long peptide linker
[1,2]. Compared to IgG molecules, Fab and scFv exhibit sig-
ni¢cantly improved tumor speci¢city and intratumoral pene-
tration [3^5]. However, the rapid blood clearance and mono-
valent nature of these small molecules result in signi¢cantly
lower quantitative tumor retention of scFv and Fab fragments
[3,6].
Recently, attention has focused upon the generation of
scFv-based molecules with molecular weights in the range of
the renal threshold for ¢rst pass clearance. Construction of
such molecules can be achieved by shortening the linker be-
tween the VH and VL domains in scFv. Reduction of the
linker length to shorter than 12 residues prevents the mono-
meric con¢guration of the scFv molecule and favors intermo-
lecular VH-VL pairings with formation of a 50 kDa non-co-
valent scFv dimer ‘diabody’ [7,8]. Prolonged tumor retention
in vivo and higher tumor to blood ratios reported for dia-
bodies over scFv monomers result both from the reduced
kidney clearance and higher avidity [9,10]. ScFv molecules
constructed by direct fusion of the C-terminal residue of VH
to N-terminal residue of VL (i.e. without any linker sequence)
can form a trimer ‘triabody’ with a molecular mass of 75^80
kDa and three antigen binding sites [8,11].
We recently described the construction and characterization
of an scFv antibody fragment speci¢c for the human B-cell
antigen CD19 [12]. The CD19 antigen is expressed on virtu-
ally all B-lineage malignancies from acute lymphoblastic leu-
kemia (ALL) to non-Hodgkin’s lymphoma (NHL) [13]. More-
over, it is not shed and is absent from hemopoietic stem cells,
plasma cells, T-cells and other tissues. CD19 is therefore one
of the best targets for immunotherapy of B-cell malignancies.
In order to develop an e¡ective means for the delivery of
radionuclides to a tumor site, we constructed a set of anti-
CD19 scFv fragments, in the present study, with a linker
comprising 0, 1 and 10 residues. We observed the quantitative
formation of diabodies by scFv-10 and triabodies by scFv-0.
Anti-CD19 scFv with a linker of one amino acid residue
formed exclusively ‘tetrabodies’. A comparison of the in vitro
binding characteristics of the diabody, triabody and tetrabody
to CD19 cells demonstrated some surprising di¡erences.
2. Materials and methods
2.1. Vector constructions
The plasmid pHOG21-KCD19 encoding an scFv fragment with an
18 amino acid linker (scFv-18) speci¢c for human CD19 [12] was used
as a material for all of the constructs. To create anti-CD19 scFv-10, a
VH gene was cut with NcoI/HindIII from the plasmid pHOG21-
KCD19 and recloned into the NcoI/HindIII linearized vector
pHOG3-19 originally encoding the hybrid VH3-VL19 scFv [14]. For
the construction of genes encoding scFv-0 and scFv-1, the PCR frag-
ments of the VH domain of anti-CD19 were generated using the
primers DP1, 5P-TCA CAC AGA ATT CTT AGA TCT ATT AAA
GAG GAG AAA TTA ACC and either VH/S, 5P-GAG CAA GAT
ATC GGA GAC GGT GAC TGA GGT TCC, or VH/SS, 5P-GAG
CAA GAT ATC TGA GGA GAC GGT GAC TGA GGT TCC,
respectively. The resulting PCR fragments were digested with NcoI
and EcoRV and ligated with the NcoI/EcoRV linearized plasmid
pHOG-KCD19. All sequences encoding scFv fragments were veri¢ed
by the dideoxynucleotide method [15].
2.2. Protein expression and puri¢cation
For expression of scFv fragments, the plasmids were transformed
into Escherichia coli K12 strain XL1-Blue (Stratagene, La Jolla, CA,
USA). Transformed bacteria were grown at 37‡C in shake £asks con-
taining 2UYT medium with 0.1 g/l ampicillin and 100 mM glucose.
IPTG induction and isolation of periplasmic extracts were performed
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as previously described [16,17]. For isolation of scFv fragments, the
culture supernatant and the soluble periplasmic extract were com-
bined and concentrated using Amicon YM10 membranes with a 10
kDa cut-o¡ (Amicon, Witten, Germany) followed by thorough dialy-
sis against 50 mM Tris-HCl, 1 M NaCl, pH 7.0. Puri¢cation was
achieved by immobilized metal a⁄nity chromatography (IMAC) us-
ing a Cu2-charged Chelating Sepharose (Pharmacia, Freiburg, Ger-
many), as described [17]. The ¢nal puri¢cation was achieved by ion-
exchange chromatography on a MonoQ HR5/5 column (Pharmacia)
in 20 mM Tris-HCl, pH 8.0 with a linear 0^1 M NaCl gradient. All
puri¢cation procedures were performed at 4‡C.
The bispeci¢c CD3UCD19 diabody was isolated as previously de-
scribed [14].
2.3. SDS-PAGE and size-exclusion chromatography
SDS-PAGE was performed according to Laemmli [18] under reduc-
ing conditions. Analytical gel ¢ltration of the scFv preparations was
performed on a calibrated Superdex 200 HR10/30 column (Pharma-
cia) in PBSI (15 mM Na-phosphate, 0.15 M NaCl, 50 mM imidazole,
pH 7.0). Sample volume and £ow rate were 50 Wl and 0.5 ml/min,
respectively.
2.4. Flow cytometry and a⁄nity determination
The human CD19 B-cell line JOK-1 was used for £ow cytometry
as previously described [14]. The apparent a⁄nities of recombinant
antibody molecules were determined from competitive inhibition as-
says [14]. Brie£y, increasing concentrations of puri¢ed antibody frag-
ment were added to a subsaturating concentration of FITC-labeled
mAb HD37 (anti-CD19) and were incubated with JOK-1 cells. Fluo-
rescence intensities of stained cells were measured using a FACScan
£ow cytometer (Becton Dickinson, Mountain View, CA, USA). Bind-
ing a⁄nities were calculated according to the following equation:
KDI = IC50/(1+[FITC-mAb]/KDmAb), where I is the unlabeled inhib-
itor (diabody, triabody or tetrabody), [FITC-mAb] is the concentra-
tion of FITC-labeled mAb HD37, KDmAb is the binding a⁄nity of
mAb and IC50 is the concentration of inhibitor that yields 50% inhib-
ition of binding. An a⁄nity constant (KD) value of 0.4 nM was as-
signed to mAb HD37 [14].
2.5. Cell surface retention assay
In vitro cell surface retention assays were performed at 37‡C essen-
tially as described [10] except that the detection of the retained anti-
body fragments was performed using anti-c-myc mAb 9E10 (IC
Chemikalien, Ismaning, Germany) followed by FITC-labeled anti-
mouse IgG. Kinetic dissociation constants (koff ) were calculated using
a ¢rst order equation Ft = F0Ue3kt, where Ft is £uorescence at time t,
F0 is £uorescence at time 0 and k is koff . The half-life (t1=2) for dis-
sociation of antibody fragments was calculated from the equation
t1=2 = ln 2/koff .
3. Results
3.1. ScFv construction, expression and puri¢cation
The anti-CD19 scFv gene construct [12], in which the VH
and VL domains were linked with the 18 residue YOL linker
(scFv-18), was used as a template to create new oligomeric
scFv species (Fig. 1a). ScFv-10 was constructed using a 10
amino acid linker mainly comprising N-terminal residues
from the CH1 domain that has been successfully used previ-
ously for making a bispeci¢c CD3UCD19 diabody [14]. The
other two scFv genes were constructed by ligating the codon
for C-terminal VH-Ser112 with N-terminal VL-Asp1 for scFv-0
and C-terminal VH-Ser113 with N-terminal VL-Asp1 for scFv-1
(numeration is given according to Kabat et al. [19]). All scFv
fragments were produced in E. coli by secretion into the bac-
terial periplasm. The soluble antibody fragments were isolated
from periplasmic extracts and culture medium by two chro-
matographic steps with typical yields of 0.8^1.0 mg per 1 l of
shake £ask culture and with a purity greater than 95% (Fig.
2).
3.2. Protein analysis
Gel ¢ltration on a calibrated Superdex 200 column demon-
strated that the scFv-18 protein was distributed between three
peaks with apparent molecular masses of 29 (40% of total
material), 56 (55%) and 115 kDa (5%), corresponding to
scFv monomer, dimer and tetramer, respectively (Fig. 3a).
In contrast, scFv-10 appeared to be predominantly dimeric
(diabody) with only a small proportion of tetramers (Fig.
3b). Size-exclusion chromatography of both scFv-1 and
scFv-0 yielded single symmetrical peaks with apparent molec-
ular masses of 115 (tetramer) and 87 kDa (trimer), respec-
tively (Fig. 3c, d).
Flow cytometry experiments demonstrated a speci¢c inter-
action of all the scFv fragments with CD19 JOK-1 cells. The
£uorescence intensities obtained for scFv-1 (tetrabody) were
somewhat higher than those for scFv-0 (triabody) and scFv-10
(diabody) over a wide range of protein concentrations (Fig.
4a). Similarly, the signals for scFv-0 were somewhat higher
than those for scFv-10. These di¡erences might result from a
Fig. 1. Expression cassettes for anti-CD19 scFv constructs. a: Monospeci¢c constructs with various linker peptides. C-terminal sequences of VH
and N-terminal sequences of VL are underlined. The linker peptide is shown in bold. b: CD3UCD19 diabody. The sequences of linkers are
shown below the diagram. The locations of ribosome binding site (rbs), pelB leader (pelB), c-myc epitope (c-myc), hexahistidine tag (his6) and
stop codon (Stop) are indicated.
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gain in a⁄nity through avidity that could be expected for
trimeric or tetrameric molecules but they could also re£ect
the number of c-myc epitopes used for the immunodetection
of each scFv oligomer. We therefore analyzed the apparent
a⁄nities of the scFv fragments by competitive binding to
human JOK-1 cells in the presence of FITC-labeled anti-
CD19 mAb HD37 (Fig. 4b). The relative a⁄nities were calcu-
lated from the corresponding IC50 values. Due to the presence
of di¡erent molecular forms in scFv-18 preparations (Fig. 3a),
instead of the parental scFv monomer we used the well char-
Fig. 2. Reducing SDS-PAGE of puri¢ed antibody fragments. Lanes:
M, MW markers; 1, bispeci¢c CD3UCD19 diabody; 2, scFv-10; 3,
scFv-0; 4, scFv-1. The gel was stained with Coomassie brilliant
blue.
Fig. 3. Size-exclusion FPLC of anti-CD19 antibody fragments on a
calibrated Superdex 200 HR10/30 column. a: scFv-18, b: scFv-10,
c: scFv-1 and d: scFv-0.
Fig. 4. Analyses of antigen binding activities of antibody fragments.
a: Direct binding to CD19 JOK-1 cells as determined by £ow cy-
tometry. b: Inhibition of binding of FITC-labeled mAb HD37 to
JOK-1 cells. c : Cell surface retention in vitro at 37‡C.
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acterized bispeci¢c CD3UCD19 diabody [14] as an example
of monovalent binding to a CD19 cell surface. The bispeci¢c
diabody comprising two hybrid scFv fragments (VH3-VL19
and VH19-VL3) was puri¢ed to homogeneity (Fig. 2, lane 1)
and appeared upon gel ¢ltration as a single peak with a mo-
lecular mass of 50^55 kDa (data not shown). Results of in-
hibition experiments demonstrated that scFv-0 (triabody)
bound CD19 with an a⁄nity almost identical to that of the
CD3UCD19 diabody, whereas scFv-10 (diabody) and scFv-1
(tetrabody) demonstrated approximately 1.5- and 2.5-fold in-
creases in a⁄nity, respectively (Table 1).
To investigate the biological relevance of the di¡erences in
a⁄nity values of the scFv fragments, their in vitro retention
on the surface of CD19-positive cells incubated at 37‡C was
determined by £ow cytometry (Fig. 4c). The scFv-10 (dia-
body) had a relatively short retention half-life (t1=2) on
CD19 cells, almost identical to the t1=2 of the bispeci¢c dia-
body (Table 1). In contrast, scFv-1 (tetrabody) was retained
2.5-fold longer than the bispeci¢c diabody. Surprisingly, scFv-
0 (triabody) demonstrated the shortest half-life, suggesting
that only one antigen binding site of this trimer interacts
with the cell surface (Fig. 4c, Table 1).
4. Discussion
The design of linker length in this study was based on the
observation that shortening the distance between VH and VL
domains in scFv below 12 residues forces an intermolecular
pairing of domains into dimers, termed diabodies [7,8]. Direct
fusion of VH and VL domains without any linker has been
shown to further constrain the domain association, resulting
in trimers, termed triabodies [8,11,20]. The C-terminal residue
in the VH domain of the triabodies was either Ser112 [8] or
Ser113 [11,20]. Even one additional amino acid between the VH
and VL domains was enough to provide the extra £exibility
required for the formation of a diabody instead of a triabody.
To obtain higher valency constructs for the HD37 anti-
CD19 scFv, we constructed two zero linker scFv fragments
with and without Ser113 residue at the VH-VL junction, named
scFv-1 and scFv-0, respectively. As expected, scFv-10 formed
mainly dimers and scFv-0 formed only trimers (Fig. 3b, d).
Both were shown to bind CD19 by £ow cytometry. In con-
trast to previously described scFv fragments containing the
VH domain linked to VL via Ser113 that formed either dimers
[7] or trimers [11,20], our scFv-1 exclusively formed tetrameric
molecules with apparent molecular mass of 115 kDa (Fig. 3c).
The tetramerization of such scFv antibody fragments with one
residue linker is described here for the ¢rst time. Since our
HD37 scFv e¡ectively forms dimers even with a linker of 18
residues (Fig. 3a), the observed tetramerization might be de-
pendent on the particular antibody fragment and its folding
history [21].
Multiple binding to surface-bound antigens is dependent on
both the correct orientation of VH-VL pairs in a multivalent
antibody complex and on epitope accessibility. Surprisingly,
triabodies demonstrated the worst antigen binding character-
istics among the examined scFv fragments. These results sug-
gest that the anti-CD19 triabody can only bind monovalently
to its cell surface anchored antigen. Inhibition experiments
demonstrated an increase in a⁄nity for scFv-10 (diabody)
and scFv-1 (tetrabody) (Fig. 4b, Table 1), but only the tetra-
body had a signi¢cantly lower dissociation rate compared to a
monovalent binder (bispeci¢c diabody) from the cell surface
(Fig. 4c, Table 1). Although the tetrabody has four potentially
active antigen binding sites, only two of them seem to be
involved in binding cell anchored CD19. This conclusion
comes from the similarity of retention half-lives for the anti-
CD19 tetrabody (26.6 min, this study) and a recently con-
structed bispeci¢c CD3UCD19 tandem diabody which has
two CD19 binding sites (24.3 min, Kipriyanov et al., manu-
script submitted).
The solution of the crystal structure of a diabody [22]
showed that the VH domain of one chain is paired with VL
domain of the other chain and vice versa. The triabody has
three Fv heads with the polypeptides arranged in a cyclic,
head-to-tail fashion [20]. It is tempting to speculate that the
tetrabody described here has similar domain arrangement
with a symmetric tetrameric conformation and less sterical
constraints than the triabody. Rough estimations indicate
that diagonal Fv modules in a square tetrabody can span
distances up to 100 Aî , signi¢cantly higher than distances be-
tween antigen binding sites in diabodies (65 Aî [22]) and tria-
bodies (75 Aî [20]). Tetrabodies with their molecular mass of
115 kDa easily exceed the renal threshold for ¢rst pass elim-
ination and should, therefore, exhibit signi¢cantly prolonged
pharmacokinetics in comparison with scFv monomers and
dimers. Tetrabodies might therefore be very useful molecules
for tumor imaging and therapy.
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